FFO
AUPH icon

Fortitude Family Office’s Aurinia Pharmaceuticals AUPH Stock Holding History

Fortitude Family Office’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.88K Hold
178
– – ﹤0.01% 1847
2026
Q2 		$3.02K Buy
+178
New +$2.84K ﹤0.01% 1305

Other funds holding AUPH

JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.49B AUM 10.8% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $540M AUM 34.92% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Fortitude Family Office's AUPH Position: Q3 2026 in Review

Fortitude Family Office held its Aurinia Pharmaceuticals (AUPH) position steady in Q3 2026 at 178 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #1847.

Fortitude Family Office first reported a position in AUPH in Q2 2026 and has held it in 2 quarters since. The position peaked at $3.02K in Q2 2026. 11 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • Fortitude Family Office held 178 shares of Aurinia Pharmaceuticals worth $2.88K as of Q3 2026.
  • Fortitude Family Office left its Aurinia Pharmaceuticals share count unchanged in Q3 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1847 holding.
  • Fortitude Family Office first reported a position in Aurinia Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • Fortitude Family Office's Aurinia Pharmaceuticals position peaked at $3.02K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.